Bezlotoxumab  (Synonyms: BLA761046; MBL-CDB1; MDX-1388)

Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

toxin B

Bezlotoxumab (100 μg/mL, 18 h pre-treatment) neutralizes TcdB-induced TER reduction in Caco-2 and MOCK cell monolayers^[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) shows increased transport to the apical chamber of Caco-2 cells with rising TcdB concentration^[1].
Bezlotoxumab (100 μg/mL, 18 h pre-treatment) inhibits TcdB-induced TER decrease in T84 cell monolayers, with Fc-independent neutralizing effects^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bezlotoxumab (250 μg/mouse, i.p., 1 day pre-infection) improves survival of both WT and FcRn^-/- C57BL/6 mice in primary CDI model, combined with Actoxumab (HY-P99277)^[1].
Bezlotoxumab (50 mg/kg, s.c., q.d. for 4 days) enhances survival and reduces symptoms in 100 g male Syrian hamsters with CDI combined with Actoxumab^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

4914070  [NCBI]

P18177

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.54 kDa

1246264-45-8

Liquid

Colorless to light yellow

[Bezlotoxumab]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Zhang Z, et al. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection. Infect Immun. 2015 Jan;83(1):405-16.  [Content Brief]

  [2]. Navalkele BD, et, al. Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection. Biologics. 2018 Jan 18;12:11-21.  [Content Brief]

  [3]. Johnson S, et al. Bezlotoxumab. Clin Infect Dis. 2019 Feb 1;68(4):699-704.  [Content Brief]